icon-facebookicon-instagramicon-pinteresticon-soundcloudicon-twittericon-youtube
Associate Professor Peter Mollee
Associate Professor Peter Mollee

Dr Mollee practices as a consultant haematologist in clinical and laboratory haematology at the Princess Alexandra Hospital and is Associate Professor with the University of Queensland Medical School. He holds appointments with the Medical Scientific Advisory Group of Myeloma Australia and is Chairman of the Australasian Leukaemia and Lymphoma Group (ALLG) where he leads the Myeloma Subgroup Committee and co-chairs the High Grade Lymphoma Subgroup.

Dr Mollee obtained a Masters in Clinical Epidemiology with a specialisation in Research Protocol Design and has a particular interest in amyloidosis and the plasma cell dyscrasias. He heads the Myeloma Service as well as the Princess Alexandra Hospital Amyloidosis Centre which runs one of the few clinics in Australia dedicated exclusively to the care of patients with amyloidosis.

Professor Andrew Spencer
Professor Andrew Spencer

Professor Andrew Spencer is a leading clinical researcher in Multiple Myeloma (MM) with a keen interest in identifying more effective and novel treatment regimes for patients living with MM. He is interested in identifying mechanisms of MM disease progression and the different methods that can be used to detect minimal residual disease in MM and how this can be used to optimise clinical care.

Andrew is Head of the Malignant Haematology and Stem Cell Transplantation Service at The Alfred Hospital and is a Professor of Haematology with Monash

Professor Hang Quach
Professor Hang Quach

Professor Hang Quach, of the University of Melbourne is the lead haematologist for Myeloma and Director of Haematology Clinical Trials at St.Vincent’s Hospital Melbourne. She also serves as a councilor of the Specialist Medical Review Council on multiple myeloma, to the Australian Minister of Veterans' Affairs. As part of her role on the Myeloma Scientific Advisory Group (MSAG) for Myeloma Australia, Prof. Quach leads the development and biennial update of the Australian National Treatment Guideline for Multiple Myeloma, to ensure standardisation of optimal care for patients with Multiple Myeloma across Australia.

Her clinical and translational research focuses on novel therapeutics for myeloma and mechanisms of development of treatment resistance, from which she has published numerous peer-reviewed manuscripts and attracted significant research funding through competitive research grants and industry collaborations. 

John Reynolds
John Reynolds

John Reynolds is an experienced clinical trials biostatistician with collaborative research interests in the application of novel trial designs, including Bayesian adaptive designs, to blood cancer research, mainly in Multiple Myeloma and Acute Myeloid Leukaemia, and the identification and validation of markers of response and survival using methods for "statistical learning".

John is the Senior Expert Biostatistician in the Department of Clinical Haematology at The Alfred Hospital and is an Adjunct Associate Professor in the Australian Centre for Blood Diseases (ACBD) at Monash University. He has previoiusly held biostatistical positions at Monash and Deakin universities, the Peter MacCallum Cancer Centre and in a global pharmaceutical company.